干眼症研究新的进展.pdf

or acute myeloid leukemia: problems and approaches［J］． Hemato- logical，2006，91( 11) : 1513-1522． ［9］ Malfuson JV，Etienne A，Turlure P，et al． Risk factors and decision criteria for intensive chemotherapy in older patients with acute my- eloid leukemia［J］． Haematologica，2008，93( 12) : 1806-1813． ［10］ Latagliata R，Breccia M，Fazi P，et al． Liposomal daunoru2 bicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukemia［J］． Br J Hematol，2008，143 ( 5) : 681-689． ［11］ Clavio M，Vignolo L，Albarello A，et al． Adding low-dose gemtu- zumab ozogamicin to fludarabine，Ara-C and idanabicin( MY-nAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective，pi- lot，multi-centre trial and comparison with a historical cohort of pa- tients［J］． Br J Haematol，2007，138( 2) : 186-195． ［12］ 张之南，沈悌． 血液病诊断及疗效标准［M］． 2 版． 北京: 科学技 术出版社，1998: 171-173． ［13］ Qian SX，Li JY，Tian T，et al． Effect of low dose cytarabine and aclarubicin in combination with granulocyte colony stim ulating fac- tor priming( CAG regimen) on the outcome of elderly patients with acute myeloid leukemia［J］． Leuk Res，2007，31( 10) : 1383-1388． ［14］ Manoharan A，Reynolds J，Matthews J，et al． Flexible low—intensi- ty combination chemotherapy for elderly patients with acute mye- loid leukemia: a multicentre，phase Ⅱ study［J］． Drugs Aging， 2007，24( 6) : 48l-488． ［15］ Winer ES，Miller KB，Chan GW，et al． GM-CSF and low-dose cyto- sine arabinoside in high-risk elderly patients with AML or MDS ［J］． Ontology( Williston Park) ，2005，19( 4 Suppl 2) : 11-14． ［16］ Roboz GJ． Arsenic and old lace: novel app roaches in elderly pa- tients with acute myeloid leukemia［J］． Semin Hematol，2008，45 ( 3 Suppl 2) : S22-S24． ［17］ Kantarjian H，OBrien S，Cortes J，et al． Results of intensive chem- otherapy in 998 patients age 65 years or older with acute myeloid leukemia or high risk myelody splastic